Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.30 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23188095 | 0.80 | ACACB (0.34) | POLB | |
| SCHEMBL25480517 | 0.80 | POLB (0.31) | POLB | |
| SCHEMBL23188094 | 0.80 | POLB (0.31) | POLB | |
| SCHEMBL20364044 | 0.78 | NPSR1 (0.39) | NPSR1L3MBTL1GAAPOLBCNR2 | |
| SCHEMBL152945 | 0.78 | SIGMAR1 (0.40) | NPSR1L3MBTL1GAAPOLBCNR2 | |
| SCHEMBL24687767 | 0.77 | CA2 (0.42) | POLBALDH1A1 | |
| SCHEMBL13820185 | 0.77 | NPSR1 (0.36) | NPSR1L3MBTL1GAAPOLBCNR2 | |
| SCHEMBL2321287 | 0.76 | NPSR1 (0.38) | NPSR1L3MBTL1GAAPOLBCNR2 | |
| SCHEMBL16643942 | 0.76 | CYP2C9 (0.45) | NPSR1L3MBTL1GAAPOLBCNR2 | |
| SCHEMBL16643953 | 0.76 | CYP2C9 (0.45) | NPSR1L3MBTL1GAAPOLBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | NPSR1 257/4885L3MBTL1 1527/4885GAA 2714/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | NPSR1 2235/4885L3MBTL1 4338/4885GAA 3646/4885 |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | RORA, RORB, RORC | NPSR1 257/4885L3MBTL1 1527/4885GAA 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.